Mid Atlantic Financial Management Inc. ADV boosted its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 21.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,679 shares of the financial services provider’s stock after purchasing an additional 832 shares during the quarter. Mid Atlantic Financial Management Inc. ADV’s holdings in iShares Nasdaq Biotechnology ETF were worth $523,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Ellis Investment Partners LLC raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 10,590.0% in the 1st quarter. Ellis Investment Partners LLC now owns 1,761,815 shares of the financial services provider’s stock valued at $1,761,000 after acquiring an additional 1,745,334 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 32,925.6% during the 4th quarter. Deutsche Bank AG now owns 1,683,314 shares of the financial services provider’s stock valued at $162,320,000 after buying an additional 1,678,217 shares in the last quarter. State of Tennessee Treasury Department purchased a new position in shares of iShares Nasdaq Biotechnology ETF during the 4th quarter valued at about $40,732,000. Lockheed Martin Investment Management Co. raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 173.9% during the 4th quarter. Lockheed Martin Investment Management Co. now owns 417,400 shares of the financial services provider’s stock valued at $40,250,000 after buying an additional 265,000 shares in the last quarter. Finally, Main Management LLC raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 14.2% during the 4th quarter. Main Management LLC now owns 398,987 shares of the financial services provider’s stock valued at $38,474,000 after buying an additional 49,514 shares in the last quarter. Institutional investors and hedge funds own 67.92% of the company’s stock.

Shares of NASDAQ IBB opened at $102.32 on Tuesday. iShares Nasdaq Biotechnology ETF has a 1-year low of $89.01 and a 1-year high of $122.97.

ILLEGAL ACTIVITY WARNING: “Mid Atlantic Financial Management Inc. ADV Has $523,000 Holdings in iShares Nasdaq Biotechnology ETF (IBB)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/mid-atlantic-financial-management-inc-adv-has-523000-holdings-in-ishares-nasdaq-biotechnology-etf-ibb/3017629.html.

iShares Nasdaq Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Story: Fundamental Analysis and Choosing Stocks

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.